Emmyon

Emmyon is a private, preclinical-stage biotech leveraging a unique discovery platform that uses human muscle biopsy mRNA signatures to identify small molecules that reverse muscle atrophy. Its pipeline includes potential therapeutics for conditions like sarcopenia, cancer cachexia, obesity, and type 2 diabetes, as well as commercialized pet health products. Founded in 2020 and based in San Diego, the company is led by a scientifically distinguished team from Mayo Clinic and industry, and is funded in part by NIH SBIR grants.

A discovery platform that uses mRNA expression signatures from human muscle biopsies to identify small molecules with inverse gene expression profiles, thereby pinpointing candidate inhibitors of muscle atrophy. The platform is focused on natural product-derived compounds like ursolic acid and tomatidine.

In human therapeutics, competitors include biopharma companies developing myostatin inhibitors, SARMs, and other anabolic agents for muscle wasting. In pet health, competition is from established nutraceutical brands. Emmyon's differentiation lies in its human molecular signature-based discovery platform and its focus on natural product-derived chemistry with a strong IP position.